Lysosomal cathepsins B, L, and D in the development of murine experimental leukemias
Tóm tắt
Lysosomal proteases are actively involved into pathogenesis of malignant tumors. Impairments in the interaction between proteases and their inhibitors are implicated in the processes of tumor invasion and metastasis. Among proteases associated with malignant growth, cysteine cathepsins B and L and aspartic cathepsin D are considered to play the major role in the tumor development. The present study was designed to investigate the activity of cathepsins B, L, and D during the development and treatment of murine experimental leukemias and to determine correlation between these proteases and course of pathological process as well as efficiency of the chemotherapeutic treatment. P-388 leukemia was characterized by a more aggressive development and unfavorable prognosis than L1210/1 leukemia. In mice with P-388 leukemia the activity of lysosomal cathepsins B, D, and L in the tumor tissue, liver and spleen, as well as the activity of cathepsins B and L in serum were lower than activities of these enzymes in mice with L1210/1 leukemia. Changes in the activity of cathepsins in liver and spleen of leukemic mice reflected a level of aggressiveness of the tumor development and invasion of these organs with tumor cells. Treatment of these experimental leukemias resulted in the increase of cathepsin B, L and D activity in the tumor tissue, liver, spleen and the increase in cathepsin B and L activity in serum. The highest protease activity was detected in the groups of mice characterized by the highest inhibition of the tumor growth. These data demonstrate that lysosomal proteases are involved in the progression of murine experimental leukemias and elimination of tumor cells in the result of treatment. Thus, determination of the activity of cysteine and aspartic proteases can be used for evaluation of cancer malignancy, tumor sensitivity for chemotherapy and efficiency of treatment.
Tài liệu tham khảo
Turk, V., Kos, J., and Turk, B., Cancer Cell, 2004, vol. 5, pp. 409–410.
Lah, T., Kalman, E., Najjar, D., Gorodetsky, E., Brennan, P., Somers, R., and Daskal, I., Hum. Pathol., 2000, vol. 31, no. 2, pp. 149–160.
Strojan, P., Svetic, B., Smid, L., and Kos, J., Clin. Chim. Acta, 2004, vol. 344, pp. 155–161.
Sloane, J.A., Hollander, W., Moss, M.B., Rosene, D.L., and Abraham, C.R., Neurobiol. Aging, 1999, vol. 20, pp. 395–405.
Kos, J., Krasovec, M., Cimerman, N., Nielsen, H.J., Christensen, I.J., and Brunner, N., Clin. Cancer Res., 2000, vol. 6, pp. 505–511.
Kos, J., Stabuc, B., Schweiger, A., Krasovec, M., Cimerman, N., Kopitar-Jerala, N., and Vrhovec, I., Clinic. Cancer Res., 1997, vol. 3, pp. 1815–1822.
Berquin, I.M. and Sloane, B.F., Adv. Exp. Med. Biol., 1996, vol. 389, pp. 281–294.
Strojnik, T., Zajk, I., Bervar, A., Zidanik, B., Golouh, R., Kos, J., Dolenc, C., and Lah, T., Pflugers Arch., 2000, vol. 439, pp. 122–123.
Schweiger, A., Staib, A., Werle, B., Krasovec, M., Lah, T.T., Ebert, W., Turk, V., and Kos, J., Br. J. Cancer, 2000, vol. 82, pp. 782–788.
Russo, A., Bazan, V., Migliavacca, M., Zanna, I., Tubiolo, C., Tumminello, F.M., Dardanoni, G., Cajozzo, M., Bazan, P., Modica, G., Lattery, M., Tomasino, R.M., Colucci, G., Gebbia, N., and Leto, G., Clin. Cancer Res., 2000, vol. 6, pp. 178–184.
Kaledin, V.I., Nikolin, V.P., Semenova, L.A., and Godovikov, A.A., Eksper. Onkol., 1991, vol. 13, pp. 43–44.
Vaux, K.K., Kahole, N.C., and Jones, K.L., Birth Defects Res., 2003, vol. 67, pp. 403–408.
Hamano, Y., Sugimoto, H., Soubasakos, M.A., Kieran, M., Olsen, B.R., Lawler, J., Sudhakar, A., and Kalluri, R., Cancer Research, 2004, vol. 64, pp. 1570–1574.
Kogan, G., Sandula, J., Korolenko, T., Falameeva, O., Poteryaeva, O., Zhanaeva, S., Levina, O., Filatova, T., and Kaledin, V., Int. Immunopharmacol., 2002, vol. 2, pp. 775–781.
De Duve, C., Giba Foundation Symposium on Lysosomes, de Reuck, A.V., Cameron, M.P., Eds., London: Churchill, 1963, pp. 1–31.
Kirschke, H. and Wiederanders, B., Acta Histochem., 1987, vol. 82, pp. 2–4.
Wiederanders, B. and Oelke, B., Mech. Ageing Dev., 1984, vol. 24, pp. 265–271.
Lowry, O., Rosebrough, H., Farr, A., Randall, R., J. Biol. Chem., 1951, vol. 193, pp. 265–275.
Koblinski, J.E., Ahram, M., and Sloane, B.F., Clin. Chim. Acta., 2000, vol. 291, pp. 113–135.
Lah, T.T., Blejec, A., Kos, J., Gorodetsky, E., Somers, R., and Daskal, I., Clin. Cancer Res., 2000, vol. 6, pp. 578–584.
Kastelic, L., Turk, B., Kopitar-Jerala, N., Stolfa, A., Rainer, S., Turk, V., and Lah, T.T., Cancer Lett., 1994, vol. 82, pp. 81–88.
Falameeva, O.V., Korolenko, T.A., Zhanaeva, S.Y., and Kaledin, V.I., Bull. Sib. Otdel. RAMS, 2001, no. 1, pp. 37–40.
Usova, T.A., Zhanaeva, S.Y., Shandula, I., Kogan, G., and Korolenko, T.A., Byull. Eksper. Biol. Med., 2003, vol. 136, pp. 509–512.
Khalikova, T.A., Zhanaeva, S.Ya., Korolenko, T.A., Kaledin, V.I., and Kogan, G., Cancer Letters, 2004, vol. 223, pp. 1–7.
Khalikova, T.A., Poteryaeva, O.N., Pospelova, T.I., and Korolenko, T.A., Gematol. Transfusiol., 2004, vol. 49, no. 4, pp. 18–22.